United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - acetate ion (unii: 569dqm74sc) (acetate ion - unii:569dqm74sc), beta carotene (unii: 01yae03m7j) (beta carotene - unii:01yae03m7j), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), r - acetate ion 3600 [iu] - supplemental vitamins and minerals should not be prescribed for patients with hemochromatosis or wilson’s disease.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablet is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate.  animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are

United States - English - NLM (National Library of Medicine)

american health packaging - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c : calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of c

United States - English - NLM (National Library of Medicine)

avpak - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate, usp is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). - patients with hypercalcemia. patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). - patients with hypercalcemia. patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calcium acetate capsules contain calcium acetate and is excreted in human milk. human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. safety and effectiveness in pediatric patients have not been established. clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate.  animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism.  calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shin-etsu chemical co., ltd - e,e-9,11-tetradecadien-1-yl acetate; e-11-tetradecen-1-yl acetate - slow release generator (inc. flea collars) - e,e-9,11-tetradecadien-1-yl acetate biological-pheromone active 2.7 gm/400d; e-11-tetradecen-1-yl acetate biological-pheromone active 65.3 gm/400d - insecticide - apple | grape | delicious | golden delicious | granny smith | grapevine | gravenstein | jonathon | lady william | legana | red d - light brown apple moth

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

suterra llc - (e,e) 8,10 dodecadien-1-ol - aerosol - (e,e) 8,10 dodecadien-1-ol biological-pheromone-insect active 173.0 g/l - insecticide - apple crop = apple orchard | pear orchard | rosaceae - codling moth

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioglobal pty limited - 1-dodecanol; 1-dodecanol; (e,e) 8,10 dodecadien-1-ol; (e,e) 8,10 dodecadien-1-ol; tetradecanol; tetradecanol - slow release generator (inc. flea collars) - 1-dodecanol alcohol active 21.4 gm/400d; 1-dodecanol alcohol active 26.8 g/500d; (e,e) 8,10 dodecadien-1-ol biological-pheromone-insect active 39.6 gm/400d; (e,e) 8,10 dodecadien-1-ol biological-pheromone-insect active 49.5 g/500d; tetradecanol biological-pheromone-insect active 6.3 g/500d; tetradecanol biological-pheromone-insect active 5.0 gm/400d - insecticide - apple crop = apple orchard | pear | rosaceae - codling moth